error
Kurzer Serviceunterbruch am Donnerstag, 15. Januar 2026, 12 bis 13 Uhr. Sie können in diesem Zeitraum keine neuen Dokumente hochladen oder bestehende Einträge bearbeiten. Das Login wird in diesem Zeitraum deaktiviert. Grund: Wartungsarbeiten // Short service interruption on Thursday, January 15, 2026, 12.00 – 13.00. During this time, you won’t be able to upload new documents or edit existing records. The login will be deactivated during this time. Reason: maintenance work
 

Treating Acute Myeloid Leukemia with Novel Antibody-Based Therapies


Loading...

Author / Producer

Date

2019

Publication Type

Doctoral Thesis

ETH Bibliography

yes

Citations

Altmetric

Data

Abstract

Acute Myeloid Leukemia (AML) originates from hematopoietic stem and progenitor cells (HSPCs). A minority of AML patients can be cured by intensive induction chemotherapy and subsequent hematopoietic stem cell transplantation (HSCT). Unfortunately, this therapeutic intervention is no option for elderly and unfit patients, which comprise the majority of AML patients. We propose to replace intensive chemotherapeutic regimens with specific disease elimination by immunotherapy. As a target for immunotherapeutic intervention we chose the cell-of-origin antigen CD117. CD117 (c-Kit), which is a surface marker expressed on healthy HSPCs and the majority of malignant AML blast cells, plays a crucial role during hematopoiesis, as well as proliferation and differentiation of the early myleoid compartment. This thesis reports the generation and characterization of three specific therapeutic interventions targeting CD117+ AML blast cells and HSPCs. In one experimental chapter we describe the selection and characterization of novel monoclonal antibodies against murine CD117. These newly generated antibodies were shown to increase the number of early primitive myeloid precursor cells in vivo. In a second experimental chapter we report the generation and characterization of a bispecific antibody targeting human CD117 and CD3 on T cells. The bispecific antibody was able to specifically eliminate CD117-expressing AML blasts in vitro and prevented leukemia engraftment in vivo. A third experimental chapter describes the generation of Chimeric Antigen Receptor (CAR) T-cells targeting human CD117. The genetically engineered T cells were shown to efficiently eliminate CD117-expressing healthy and malignant hematopoietic cells. In a therapeutic setting, the CAR T-cells eradicated human AML in vivo in xenografted immunodeficient mice.

Publication status

published

Editor

Contributors

Examiner: Neri, Dario
Examiner : Detmar, Michael

Book title

Journal / series

Volume

Pages / Article No.

Publisher

ETH Zurich

Event

Edition / version

Methods

Software

Geographic location

Date collected

Date created

Subject

Acute myeloid leukemia (AML); Antibodies; Immunotherapy; Hematology

Organisational unit

03463 - Neri, Dario (ehemalig) / Neri, Dario (former) check_circle

Notes

Funding

Related publications and datasets